Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3 rd-generation EGFR inhibitors and outperforms other investigational 4 th-generation inhibitors ...

Title : APG990, a monoclonal antibody targeting OX40L, demonstrates safety and an extended half-life in healthy subjects (P3237) Presenter : Carl Dambkowski, M.D., Chief Medical Officer, Apogee ...

Jade Biosciences, Inc. announced that new preclinical data on its investigational anti-APRIL monoclonal antibody, JADE101, will be presented at the 62nd European Renal Association Congress in Vienna ...

Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable ...